Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...

High blood pressure, also known as hypertension, is a major risk factor for heart disease and comes with a significant ...

and suppression of renin activity. See literature. Early treatment: initially administer three 5mg IV bolus inj given at approximately 2-minute intervals; monitor BP, HR, ECG. If full IV dose ...

h Specific for underlying mechanisms (other forms of treatment, including different antihypertensive medications = might ... which suppresses plasma renin activity These disorders should be ...

The 43 patients treated with ravulizumab had a 33.2% greater reduction in average urine protein to creatinine ratio (UPCR) ...

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...

Patients with broad range of kidney function show reduced effects following discontinuation after EMPA-KIDNEY trial.

including certain antihypertensive drugs, diuretics, and NSAIDs, may be at an increased risk for kidney failure. A 2022 study conducted by researchers at the University of Waterloo and published in ...

基于优秀的循证医学证据，2024年，改善全球肾脏病预后组织（KDIGO）发布的CKD临床管理指南推荐SGLT2i作为CKD中的一线治疗药物（图3） [13] ...

The renin-angiotensin-aldosterone system (RAAS ... If your hypertension is more advanced or lifestyle changes haven't worked for you, your healthcare provider might add one or more medications.

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in ...